What smart money is saying about Sotera Health
3 funds in our archive have pitched Sotera Health — most recently Beck Mack & Oliver Portfolio in July 2026.
Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions. The firm's sterilization capabilities encompass gamma and electron beam irradiation, alongside ethylene oxide (EO) processing. Through its Nelson Labs division, Sotera Health conducts comprehensive microbiological and analytical chemistry analyses. Additionally, it offers specialized consulting to the medical device and biopharmaceutical industries. Sotera Health serves a diverse array of sectors, including medical device manufacturers, pharmaceutical companies, producers of food and agricultural products, and various commercial, advanced, and specialty application industries. Incorporated in 2017, the company was previously known as Sotera Health Topco, Inc., adopting its current name in October 2020.
Get an email when a fund buys, sells or pitches it
Position history
Between Q4 2025 and Q3 2026, 4 fund letters reported a position in Sotera Health — 2 opened or added to the position, 2 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 0 | 0 | 0 | 1 |
| Q2 2026 | 2 | 1 | 1 | 1 |
| Q1 2026 | 1 | 1 | 0 | 1 |
| Q4 2025 | 1 | 0 | 1 | 0 |
Fund activity · 4 positions · 4 moves
- New positionO'Keefe Stevens AdvisoryJune 2026
“New Position: Sotera Health (SHC)We have been following Sotera Health for several years. The business is exceptional: a sterilization duopoly with Sterigenics and Steris combined controlling an estimated 70% of the sterilization market. Sotera's Sterigenics business boasts 50% EBITDA margins, mission-critical regulated services, and cobalt-60 production that is nearly impossible to replicate. Yet we never bought it because of one thing: Warburg Pincus held a material stake and was consistently selling into the market. We do not buy high-quality businesses where forced sellers will pressure the stock regardless of fundamental improvement. We look for situations where forced sellers create dislocation, allowing us to buy a stock for cheaper than what it would trade for without such selling pressure. On the flip side, we look to sell into forced buyers pushing stock prices up irrespective of fundamentals. In early 2026, Warburg sold its last share.”
Sotera Health - May 2026
“Eight years after taking the company public, Warburg Pincus and GTCR are out. The sponsors completed a 31.8 million-share secondary in May, fully exiting their Sotera Health positions and terminating the stockholders' agreement that had given them board control.”
Sotera Health - AddedBroyhill AMMarch 2026
“we significantly increased our investments in the sectors, bringing both IQVIA and Sotera Health into our top holdings.”
Sotera Health - December 2025
“We reduced the Portfolio’s position in Sotera’s 7.375% Senior Notes due 2031 during the quarter, taking advantage of strong price appreciation.”
Sotera Health
Fund coverage · 3 theses
- Beck Mack & Oliver PortfolioJuly 2026
Sotera Health operates a regulated, capacity-constrained sterilization business with recurring revenues, high switching costs, and strong pricing power, while also offering double-digit growth at an unreflected valuation.
Read the full thesis - O’Keefe Stevens AdvisoryJune 2026
Sotera Health is a high-quality sterilization duopoly with strong margins, high switching costs, and multiple catalysts from capex normalization and litigation resolution.
Read the full thesis - Broyhill AMMarch 2026
Sotera Health is a mission-critical sterilization business with a duopoly position and valuation support despite litigation overhangs.
Read the full thesis
Read every full thesis on Sotera Health
Unlock all 3 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→